首页> 外文期刊>European Journal of Pharmacology: An International Journal >Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats.
【24h】

Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats.

机译:尼可地尔和吡格列酮的药理学预处理可减轻大鼠的心肌缺血/再灌注损伤。

获取原文
获取原文并翻译 | 示例
       

摘要

The present investigation was designed to study the cardioprotective effects of nicorandil and pioglitazone preconditioning in myocardial ischemia/reperfusion-induced hemodynamic, biochemical and histological changes in rats. Oral doses of nicorandil (3 or 6 mg/kg) and pioglitazone (10 or 20mg/kg) were administered once daily for 5 consecutive days. Rats were then subjected to myocardial ischemia/reperfusion (40 min/10 min). Heart rate and ventricular arrhythmias were recorded during ischemia/reperfusion progress. At the end of reperfusion, plasma creatine kinase-MB activity and total nitrateitrite were determined. In addition, lactate, adenine nucleotides, thiobarbituric acid reactive substances, reduced glutathione and myeloperoxidase activity were estimated in the heart left ventricle. Finally, histological examination was performed to visualize the protective cellular effects of different pretreatments. Nicorandil (3 or 6 mg/kg) was effective in attenuating the ischemia/reperfusion-induced ventricular arrhythmias, creatine kinase-MB release, lactate accumulation and oxidative stress. Nicorandil (3 mg/kg) was more effective in improving the energy production and lowering the elevated myeloperoxidase activity. Both doses of pioglitazone (10 or 20 mg/kg) were equally effective in reducing lactate accumulation and completely counteracting the oxidative stress. Pioglitazone (10 mg/kg) was more effective in improving energy production and reducing ventricular arrhythmias, plasma creatine kinase-MB release and total nitrateitrite. It seems that selective mitochondrial K(ATP) channel opening by lower doses of nicorandil and pioglitazone in the present study provided more cardioprotection against ventricular arrhythmias and biochemical changes induced by ischemia/reperfusion. Histological examination revealed also better improvement by the lower dose of nicorandil than that of pioglitazone.
机译:本研究旨在研究尼可地尔和吡格列酮预处理对大鼠心肌缺血/再灌注引起的血流动力学,生化和组织学变化的保护作用。每天一次口服尼可地尔(3或6 mg / kg)和吡格列酮(10或20mg / kg),连续5天。然后使大鼠经历心肌缺血/再灌注(40分钟/ 10分钟)。在缺血/再灌注过程中记录心率和室性心律失常。在再灌注结束时,测定血浆肌酸激酶-MB活性和总硝酸盐/亚硝酸盐。此外,估计左心室的乳酸,腺嘌呤核苷酸,硫代巴比妥酸反应性物质,谷胱甘肽减少和髓过氧化物酶活性。最后,进行组织学检查以可视化不同预处理的保护性细胞作用。尼古兰地(3或6 mg / kg)在减轻局部缺血/再灌注引起的室性心律失常,肌酸激酶-MB释放,乳酸积累和氧化应激方面有效。尼古兰地(3 mg / kg)在改善能量产生和降低升高的髓过氧化物酶活性方面更有效。两种剂量的吡格列酮(10或20 mg / kg)在减少乳酸积累和完全抵消氧化应激方面均有效。吡格列酮(10 mg / kg)在改善能量产生和减少室性心律不齐,血浆肌酸激酶-MB释放和总硝酸盐/亚硝酸盐方面更有效。似乎本研究中较低剂量的尼可地尔和吡格列酮对选择性线粒体K(ATP)通道的开放提供了更多的心肌保护作用,以抵抗由缺血/再灌注引起的室性心律不齐和生化变化。组织学检查显示,比尼格列酮低剂量的尼可地尔也可以改善病情。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号